The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 29, 2024
Filed:
May. 03, 2021
Applicant:
Btg International Limited, London, GB;
Inventor:
Udai Banerji, Sutton, GB;
Assignee:
BTG International Limited, London, GB;
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/502 (2006.01); A61K 31/519 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4745 (2013.01); A61K 31/502 (2013.01); A61K 31/519 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61K 47/643 (2017.08); A61K 47/6929 (2017.08); A61P 35/00 (2018.01); A61K 2039/545 (2013.01);
Abstract
A compound of formula I or a pharmaceutically acceptable salt or ester thereof is provided for the treatment of cancer wherein (i) the cancer is one that has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy and (ii) the treatment is with a dose of between 1 mg/mand 30 mg/mof compound per patient body surface area per administration. Method of treatment and novel dosage forms are also provided. Particularly treated are ovarian cancers, particularly those expressing a-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer.